Comparison · GLP-1
Semaglutide vs Tirzepatide · Molecule by Molecule
The two molecules behind Wegovy, Ozempic, Zepbound, and Mounjaro · what is different at the receptor level, what it means for weight loss, and how to choose.
Semaglutide and tirzepatide are the two molecules that have transformed obesity medicine in the last five years. They are not brand names · they are the active pharmaceutical ingredients sold under several different labels. Semaglutide is the molecule inside Ozempic, Wegovy, and Rybelsus. Tirzepatide is the molecule inside Mounjaro and Zepbound. Patients often arrive convinced they want a brand, but the conversation usually shortens once they understand it is really a choice between two molecules and several wrappers.
The molecule comparison matters more than the brand comparison because the molecule determines the side-effect profile, the average weight loss, the titration ladder, and the way your body adapts over time. Brand mostly determines price and labeled indication. Compounded versions of either molecule, prepared by a 503A or 503B pharmacy, share the same mechanism even though the finished product is not FDA approved.
This page goes deeper than a brand-vs-brand comparison · we cover the receptor pharmacology, the trial evidence, the practical differences in how patients feel on each, and the way insurance and compounding economics actually shape the choice in 2026.
Semaglutide vs tirzepatide · at a glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptor activity | GLP-1 agonist | Dual GLP-1 and GIP agonist |
| Brand names (US) | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Approved indications | Type 2 diabetes, chronic weight management, cardiovascular risk reduction | Type 2 diabetes, chronic weight management, obstructive sleep apnea (Zepbound) |
| Half-life | About 7 days | About 5 days |
| Dose forms | Pen injection or oral tablet (Rybelsus) | Pen injection or single-use vial |
| Maintenance dose (weight) | 2.4 mg weekly | 5, 10, or 15 mg weekly |
| Average weight loss in trials | About 15 percent (STEP 1, 68 weeks) | About 21 percent (SURMOUNT-1, 72 weeks, 15 mg) |
| Compounded availability | Yes, via 503A or 503B pharmacies with a prescription | Yes, via 503A or 503B pharmacies with a prescription |
| First FDA approval | 2017 (Ozempic, diabetes) | 2022 (Mounjaro, diabetes) |
What single-agonist vs dual-agonist actually means
Semaglutide binds and activates the GLP-1 receptor. Tirzepatide binds and activates both the GLP-1 receptor and the GIP receptor. GLP-1 and GIP are both incretin hormones · they are released by gut cells in response to nutrients and they signal the pancreas, the brain, and the gut about how to handle the meal that just arrived.
On its own, GLP-1 lowers blood sugar, slows gastric emptying, and reduces appetite by acting on hunger centers in the brain. GIP also enhances insulin secretion and appears to have a separate role in how fat tissue stores and mobilizes energy. The dual-agonist hypothesis is that hitting both receptors simultaneously produces a larger metabolic effect than hitting either alone, and so far the trial data supports it.
It is not as simple as more receptors equals more weight loss. GIP signaling alone, for example, does not produce significant weight loss. The hypothesis is that GIP changes how the body responds to GLP-1 · sensitizing fat tissue, modulating brain appetite circuits, or improving insulin response in a way that compounds the GLP-1 effect. Pharmacology research is still working out the exact mechanism, but the clinical signal is consistent.
Weight loss · what each molecule actually delivers
Semaglutide at the 2.4 mg weight-management dose produced an average 14.9 percent body-weight loss over 68 weeks in STEP 1. The lower 1.7 mg dose used in some compounded protocols produces a smaller but still clinically meaningful loss in the 8 to 12 percent range over similar timeframes.
Tirzepatide at 5, 10, and 15 mg produced 15, 19.5, and 20.9 percent average loss respectively over 72 weeks in SURMOUNT-1. SURMOUNT-3, which added intensive lifestyle support, pushed average loss above 26 percent of body weight at 84 weeks.
The most informative direct comparison is SURPASS-2 in type 2 diabetes · tirzepatide outperformed semaglutide on weight loss at every dose, with the 15 mg arm producing roughly twice the weight loss of the 1 mg semaglutide arm. The diabetes setting uses lower semaglutide doses, so the obesity-dose comparison is closer than that ratio suggests, but the molecule-level signal is real.
Side effects · what is similar, what is different
Both molecules share the same family of GI side effects · nausea, fullness, reflux, constipation or diarrhea, and reduced appetite. The intensity is highest in the first two weeks of any new dose and tapers as the body adapts. Most patients tolerate either molecule well at maintenance dosing once titration is complete.
Tirzepatide produces more diarrhea on average and more rapid early-week weight loss, especially at the 10 mg and 15 mg steps. Semaglutide produces more constipation on average and a more protracted nausea pattern. Neither molecule is reliably better tolerated than the other at the population level · individual patient response is what matters, and physicians often switch molecules if titration stalls.
Both molecules carry a boxed warning for thyroid C-cell tumors based on rodent data, contraindicate in patients with personal or family history of medullary thyroid carcinoma or MEN 2, and have rare associations with pancreatitis and gallbladder disease. The cardiovascular outcome data on semaglutide (SELECT trial) shows a 20 percent reduction in major cardiac events in patients with overweight or obesity and prior cardiovascular disease, which has driven a lot of the recent enthusiasm for the molecule beyond weight loss alone.
Compounded semaglutide vs compounded tirzepatide
When the branded products are out of reach due to cost or insurance, many patients work with their physician on a compounded version. Compounded semaglutide is the more established option · pharmacies have been preparing it longer and dose protocols are well-validated. Compounded tirzepatide is newer to the compounding pharmacy supply chain but is increasingly available with similar dose ladders.
The clinical experience on compounded versions tracks closely with the branded molecule when the compounding pharmacy uses pure active ingredient and standard dosing. The trade-off is that the finished product is not FDA-approved · the molecule is the same, but the manufacturer-level quality control and stability data is replaced by pharmacy-level USP standards plus state board oversight.
Cost-wise, compounded semaglutide is typically the most affordable starting point. Compounded tirzepatide is somewhat more expensive but still well below the branded list price. Whether the molecule difference justifies the price difference depends on your goal · if you are aiming for the highest possible weight loss and your budget allows, tirzepatide makes sense. If you are looking for steady, sustainable loss with the longest real-world track record, semaglutide is the more proven choice.
How we help patients choose
Our intake quiz assigns a starting molecule based on three inputs · your weight goal, your insurance coverage, and your tolerance for side effects. A patient with a moderate weight goal, a balanced budget, and a preference for the gentler ramp-up usually starts on semaglutide. A patient with a high weight goal, no insurance for either branded product, and a willingness to titrate through stronger early side effects often starts on tirzepatide.
We also factor in your timeline. The pace=fastest path in the quiz biases moderate-weight balanced-budget users toward tirzepatide because the trial data supports a faster initial trajectory. Slow-and-steady users default toward semaglutide for the same reason in reverse. Both paths are clinically reasonable starting points and both can be revised at the four-week or eight-week check-in.
Whichever molecule you start on, the structure is the same · physician evaluation, baseline labs when indicated, four-week titration, monthly check-ins, and dose adjustment based on response and tolerance. The molecule is the most visible decision but it is not the most important one. The most important one is whether you stay on therapy long enough to see the result.
Frequently asked questions
Is tirzepatide better than semaglutide for weight loss?
On average, yes · trial data show tirzepatide produces a higher percent body-weight loss at maintenance dosing. Individual response varies and some patients lose more on semaglutide. The safety profile is similar at the molecule level.
Can I switch from semaglutide to tirzepatide?
Yes. The standard switch is to stop semaglutide, wait one week, then start tirzepatide at the lowest dose with a normal four-week titration. Most patients keep the weight they have already lost during the transition.
Are compounded versions the same as the brand?
The active molecule is the same. The finished product is not FDA-approved · it is prepared by a state-licensed compounding pharmacy under USP standards. Quality varies by pharmacy, which is why physician supervision and pharmacy choice matter.
Which one is cheaper without insurance?
Branded semaglutide and tirzepatide are both above 1,000 USD per month at list price. Compounded semaglutide is typically the most affordable cash-pay option, with compounded tirzepatide somewhat higher but still well below branded prices.
Let Dr. Linda pick your starting molecule
The two-minute quiz assigns semaglutide or tirzepatide based on your weight goal, your insurance, and your tolerance for side effects. No charge to find out.
This page is educational and is not a substitute for medical advice. Semaglutide and tirzepatide are prescription molecules. Eligibility, dosing, and pricing are determined after a clinical evaluation by a licensed physician.